# OLIVE RESOURCE CAPITAL INC. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024 (EXPRESSED IN CANADIAN DOLLARS UNLESS OTHERWISE STATED) (UNAUDITED)

# **Notice to Reader**

The accompanying condensed consolidated interim financial statements of Olive Resource Capital Inc. (the "Company") have been prepared by and are the responsibility of management. The condensed consolidated interim financial statements have not been reviewed by the Company's auditors.

Condensed Interim Consolidated Statements of Financial Position

(Expressed in Canadian Dollars unless otherwise stated)

(Unaudited)

	Se	eptember 30, 2024	December 3 2023		
ASSETS Cash Amounts receivable Publicly traded investments (Note 3(a)) Non-public loans and convertible debentures (Note 3(c)) Prepaid expenses Restricted cash (Note 4)	\$	506,212 8,176 3,774,018 1,521,465 22,342 25,000	\$	1,761,919 8,176 2,884,159 1,527,573 39,523 25,000	
Non-public investments (Note 3(b)) Total assets	\$	1,103,194 6,960,407	\$	881,907 7,128,257	
LIABILITIES AND EQUITY Liabilities Accounts payable and accrued liabilities (Notes 5 and 10) Deferred gain on acquisition of investments (Note 6)	\$	107,987 81,591	\$	76,729 81,591	
Total liabilities		189,578		158,320	
<b>Shareholders' equity</b> Share capital (Note 7) Contributed surplus (Note 8) Deficit		15,084,841 433,249 (8,747,261)		15,172,132 397,351 (8,599,546)	
Total shareholders' equity		6,770,829		6,969,937	
	\$	6,960,407	\$	7,128,257	

Nature of Operations (Note 1)

Commitments and Contingencies (Note 13)

Approved by the Board of Directors:

"Samuel Pelaez" Director

"Derek Macpherson" Director

Condensed Interim Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income (Expressed in Canadian Dollars unless otherwise stated)

(Unaudited)

		Three Mo Septe 2024		ns Ended per 30, 2023		Nine Mor Septe 2024		s Ended ber 30, 2023
Revenues								
	\$	2,071	\$	(5,975,001)	\$	68,582	\$	(5,369,237)
Unrealized gain on investments (Note 3)	Ψ	265,754	Ψ	6,154,743	Ψ	52,341	Ψ	6,873,931
Interest and dividend income		67,433		(3,337)		268,044		64,624
Total revenues		335,258		176,405		388,967		1,569,318
Operating expenses								
Salaries and benefits (Note 10(b))		11,592		11,110		34,776		37,381
Professional fees (Note 10(a)(i)(ii)(iii)(iv)(v))		101,305		100,873		298,609		364,708
Shareholder information		9,257		9,046		28,813		39,434
General and administrative		35,962		27,227		104,981		71,361
Investor relations		5,085		4,831		18,755		15,001
Stock-based compensation (Notes 8 and 10(b))		9,538		10,858		35,898		43,183
Foreign exchange loss (gain)		20,118		(5,278)		14,850		8,142
Total operating expenses		192,857		158,667		536,682		579,210
Income (Loss) for the period	\$	142,401	\$	17,738	\$	(147,715)	\$	990,108
Basic and diluted net income (loss)								
· · · · ·	\$	0.00	\$	0.00	\$	(0.00)	\$	0.01
Weighted average number of shares outstanding - basic and diluted (Note 9)		,174,709	1	11,768,709	1(	09,174,709		11,630,587

The accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements.

Condensed Interim Consolidated Statements of Changes in Shareholders' Equity (Expressed in Canadian Dollars unless otherwise stated) (Unaudited)

	Number of Shares	Share Capital	C	Contributed Surplus	Deficit	Total
Balance, December 31, 2022	110,768,709	\$ 15,208,812	\$	328,053	\$ (9,230,166)	\$ 6,306,699
Share repurchase (note 7)	-	(275,605)		-	214,075	(61,530)
Shares issued in settlement of accrued liability (note 5)	1,000,000	35,000		-	-	35,000
Share-based compensation (Note 8)	-	-		43,183	-	43,183
Net income for the period	-	-		-	990,108	990,108
Balance, September 30, 2023	111,768,709	\$ 14,968,207	\$	371,236	\$ (8,025,983)	\$ 7,313,460
Balance, December 31, 2023	109,174,709	\$ 15,172,132	\$	397,351	\$ (8,599,546)	\$ 6,969,937
Share repurchase (note 7)	-	(87,291)		-	-	(87,291)
Share-based compensation (Note 8)	-	-		35,898	-	35,898
Net loss for the period	-	-		-	(147,715)	(147,715)
Balance, September 30, 2024	109,174,709	\$ 15,084,841	\$	433,249	\$ (8,747,261)	\$ 6,770,829

The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.

#### Condensed Interim Consolidated Statements of Cash Flows (Expressed in Canadian Dollars unless otherwise stated) (Unaudited)

Nine Months Ended September 30,	2024	2023
Operating activities		
Net (loss) income for the period	\$ (147,715)	990,108
Adjustments for:		
Net (gain) on investments (note 3)	(120,923)	(1,504,694)
Accrued interest income	(74,716)	(23,798)
Stock-based compensation	35,898	43,183
	(307,456)	(495,201)
Changes in non-cash operating capital, public-traded investments, non-public	(307,430)	(430,201)
investments and non-public loans and convertible debentures:		
Amounts receivable	-	(18)
Prepaid expenses	17,181	16,201
Accounts payable and accrued liabilities	31,258	(212,559)
Public-traded investments	(909,399)	3,370,189
Non-public investments	-	(107,000)
Non-public loans and convertible debentures	-	(151,550)
Net cash (used in) provided by operating activities	(1,168,416)	2,420,062
Financing activities		
Share repurchase	(87,291)	(60,530)
Net cash used in financing activities	(87,291)	(60,530)
	• • •	
Net change in cash and cash equivalents	(1,255,707)	2,359,532
Cash and cash equivalents, beginning of period	1,761,919	301,380
Cash and cash equivalents, end of period	\$ 506,212	\$ 2,660,912

The accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements.

Notes to Condensed Interim Consolidated Financial Statements September 30, 2024 (Expressed in Canadian Dollars unless otherwise stated) (Unaudited)

### 1. Nature of Operations

Olive Resource Capital Inc. ("Olive" or the "Company") is a resource-focused merchant bank and investment company with a portfolio of publicly listed and private securities. The Company's assets consist primarily of investments in natural resource companies in all stages of development. The Company is a publicly listed company incorporated the Canada Business Corporations Act. The Company's shares are listed on the TSX Venture Exchange. The Company's head office is located at 82 Richmond St. East, Toronto, Ontario, M5C 1P1.

### 2. Material Accounting Policies

#### Statement of compliance

The Company applies International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). These unaudited condensed consolidated interim financial statements have been prepared in accordance with International Accounting Standard 34, Interim Financial Reporting. Accordingly, they do not include all of the information required for full annual financial statements required by IFRS as issued by the IASB.

The policies applied in these unaudited condensed consolidated interim financial statements are based on IFRS issued and outstanding as of November 26, 2024, the date the Board of Directors approved the statements. The same accounting policies and methods of computation are followed in these unaudited condensed consolidated interim financial statements as compared with the most recent annual financial statements as at and for the year ended December 31, 2023, except as noted below. Any subsequent changes to IFRS that are given effect in the Company's annual financial statements for the year ending December 31, 2024 could result in restatement of these unaudited condensed consolidated interim financial statements.

#### New accounting standard adopted

IAS 1 – Presentation of Financial Statements ("IAS 1") was amended in January 2020 to provide a more general approach to the classification of liabilities under IAS 1 based on the contractual arrangements in place at the reporting date. The amendments clarify that the classification of liabilities as current or noncurrent is based solely on a company's right to defer settlement at the reporting date. The right needs to be unconditional and must have substance. The amendments also clarify that the transfer of a company's own equity instruments is regarded as settlement of a liability, unless it results from the exercise of a conversion option meeting the definition of an equity instrument. The amendments are effective for annual periods beginning on January 1, 2024 and had no significant impact on the unaudited condensed interim consolidated financial statements as a result of its adoption.

#### Recent accounting pronouncements

Certain new accounting standards and interpretations have been published that are not mandatory for the current period and have not been early adopted. These standards are not expected to have a material impact on the Company in the current and future reporting periods.

Notes to Condensed Interim Consolidated Financial Statements September 30, 2024 (Expressed in Canadian Dollars unless otherwise stated) (Unaudited)

#### 3. Investments

### (a) Public-traded investments

(c) - como d'autor interente 	As at	December 3	1, 2023	Transactions during nine months end September 30, 2	ed	As at September 30, 2024			
	Cost	Cumulative Unrealized Gain (Loss)	Fair Value	Acquisition cost (Proceeds on Realized Disposition) Gain (Loss)	Change in unrealized Gain (Loss)	Fair value	Securities Held	Cost	
Nevada Zinc Corporation ("Nevada Zinc") <sup>(2)</sup> \$ Other investments in public companies <sup>(1)</sup>	2,569,664 2,586,881	\$ (2,119,704) \$ (152,682)	449,960 2,434,199	\$ (8,595) \$ (53,495) 868,894 122,077	\$ (387,870) 348,848	\$- 3,774,018	16,224,406 15,228,677	\$   2,507,574 3,577,852	
	5,156,545	\$ (2,272,386) \$	2,884,159	\$ 860,299 \$ 68,582	\$ (39,022)	\$ 3,774,018	:	\$ 6,085,426	

<sup>(1)</sup> The Company holds numerous smaller investments in public companies. These investments are presented in aggregated format.

<sup>(2)</sup> The Company owns more than 10% of the voting rights attached to the outstanding voting securities of Nevada Zinc. This may limit the Company's ability to monetize or dispose of the securities of Nevada Zinc.

Notes to Condensed Interim Consolidated Financial Statements September 30, 2024 (Expressed in Canadian Dollars unless otherwise stated) (Unaudited)

### 3. Investments (continued)

### (a) Public-traded investments (continued)

	Transactions during the year ended As at December 31, 2022 December 31, 2023 As at December 31,									
	Cost	Cumulative Unrealized Gain (Loss)	Fair Value	Acquisition cost (Proceeds on Disposition)	Realized Gain (Loss)	Change in unrealized Gain (Loss)	Fair value	Securities Held	Cost	
Nevada Zinc Corporation ("Nevada Zinc") <sup>(2)</sup> Minera Alamos Inc. ("Minera Alamos")		\$ (1,759,686)\$	810,153	\$ (198)	\$ 23	\$ (360,018)	\$ 449,960	17,998,406	\$ 2,569,664	
shares Rockcliff Metals Corporation ("Rockcliff") shares	61,206 9,619,544	409,594 (7,963,186)	470,800 1,656,358	(400,244) (3,815,299)	339,038 (5,804,245)	(409,594) 7,963,186	-	-	-	
Other investments in public companies <sup>(1)</sup>	1,495,334 \$13,745,923	(230,357) \$ (9,543,635) \$	1,264,977 4,202,288	1,512,043 \$2,703,698)	(420,496) \$ (5,885,680)	77,675 \$ 7,271,249	2,434,199 \$ 2,884,159	11,428,658	2,586,881 \$ 5,156,545	

<sup>(1)</sup> The Company holds numerous smaller investments in public companies. These investments are presented in aggregated format.

<sup>(2)</sup> The Company owns more than 10% of the voting rights attached to the outstanding voting securities of Nevada Zinc. This may limit the Company's ability to monetize or dispose of the securities of Nevada Zinc.

Notes to Condensed Interim Consolidated Financial Statements September 30, 2024 (Expressed in Canadian Dollars unless otherwise stated) (Unaudited)

### 3. Investments (continued)

## (b) Non-public Equity Investments

	As at Dec	cember 31, 20	As at S	As at September 30, 2024						
	Cost	Cumulative Unrealized Gain	Fair Value	Purchase	Transfer to public investments	Interest income in shares	Change in Unrealized gain (loss)	Fair Value	Securities Held	Cost
Other non-public investment	\$1,243,759	\$ (361,852) \$	881,907	\$ 100,100	\$ (51,000)	\$ 59,787	\$ 112,400	\$1,103,194	6,311,926	\$1,352,646

		Transactions during the year ended	
	As at December 31, 20	December 31, 2023	As at December 31, 2023
	Cumulative Unrealized Fair Cost Gain Value	Change in Realized Unrealized Purchase Gain (Loss) (loss)	Fair Securities Value Held Cost
Other non-public investment	\$ 616,263 \$ 16,604 \$ 632,86	\$647,692 \$ (20,196) \$ (378,456)	\$ 881,907 5,853,059 \$1,243,759

Notes to Condensed Interim Consolidated Financial Statements September 30, 2024 (Expressed in Canadian Dollars unless otherwise stated) (Unaudited)

### 3. Investments (continued)

#### (c) Non-public loans and convertible debentures

				Transaction nine mor					
	As	at Decem	oer 31, 2023	Septemb	oer 30, 2	2024	As at \$	September	30, 2024
	Cost	Cumulative Unrealized Gain	Fair Value	nterest ncome		realized n (loss)	Fair Value	Securities Held	Cost
Non-public investments in loans and convertible debentures	\$1,466,973	\$ 60,600	\$1,527,573	\$ 14,929	\$	(21,037)	\$1,521,465	1,028,750 \$	51,466,973

	As a	t Decembe	r 31, 2022	2	Transactions year e Decembe	nded	ne	As at December 31, 2023		
	Cost	Cumulative Unrealized Gain	Fair Value	Acquisition costs (Proceeds on Disposition)	Realized gain (loss)	Interest income	unrealized gain (loss)	Fair Value	Securities Held	cost
Non-public investments in loans and convertible debentures	\$1,427,989	\$ 61,800	\$1,489,789	\$ (323,142)	\$ 362,126 \$	36,071	\$ (37,271)	\$1,527,573	1,028,750 \$ <sup>^</sup>	1,466,973

(i) The Company holds senior unsecured convertible debentures of Guided Therapeutics Inc. with a principal value of US\$250,000. The debentures are past due and the Company is working with the debenture issuer to rectify the situation.

Notes to Condensed Interim Consolidated Financial Statements September 30, 2024 (Expressed in Canadian Dollars unless otherwise stated) (Unaudited)

## 3. Investments (continued)

### (d) Total investments

	As at	December 3	Transactions during the nine months ended September 30, 2024								As at September 30, 2024		
	Cost	Cumulative Unrealized Gain (loss)	Fair Value	Net purchase (disposition)	Realized Gain		nterest income n shares	t	Transfer o public vestment	Interes incom		Net Unrealized Gain (loss)	Fair Value
Public investments Non-public equity	\$ 5,156,545	\$ (2,272,386)	\$ 2,884,159	\$ 860,299	\$ 68,582	\$	-	\$	-	\$-		\$ (39,022)	\$ 3,774,018
investments Non-public investments in	1,243,759 Ioans	(361,852)	881,907	100,100	-		59,787		(51,000)	-		112,400	1,103,194
and convertible debenture		60,600 <b>\$ (2,573,638)</b>	1,527,573 \$ 5,293,639	- \$ 960,399	 - 68,582	\$	- 59,787	•	- (51,000)	14,9	29 <b>29</b>	(21,037) <b>52,341</b>	1,521,465 \$ 6,398,677

- 10 -

Notes to Condensed Interim Consolidated Financial Statements September 30, 2024 (Expressed in Canadian Dollars unless otherwise stated) (Unaudited)

## 3. Investments (continued)

### (d) Total investments (continued)

	As a	it December 3 <sup>,</sup>	1, 2022	tł	ansactions ne year end ecember 3 <sup>°</sup>	ed	As at December 31, 2023
	Cost	Cumulative Unrealized Gain (loss)	Fair Value	Net purchase (disposition)	Realized Gain	Interest Net Unrealized income Gain (loss)	Fair Value
Public investments Non-public equity	\$13,745,923	\$ (9,543,635)	\$ 4,202,288	\$ (2,703,698)	\$ (5,885,680)	\$ - \$ 7,271,249	\$ 2,884,159
investments Non-public investments in lo	616,263 <b>ans</b>	16,604	632,867	647,692	(20,196)	- (378,456)	881,907
and convertible debentures	1,427,989	61,800	1,489,789	(323,142)	362,126	36,071 (37,271)	1,527,573
	\$15,790,175	\$ (9,465,231)	\$ 6,324,944	\$ (2,379,148)	\$ (5,543,750)	\$ 36,071 \$ 6,855,522	\$ 5,293,639

- 11 -

Notes to Condensed Interim Consolidated Financial Statements September 30, 2024 (Expressed in Canadian Dollars unless otherwise stated) (Unaudited)

### 4. Restricted Cash

The Company has a corporate credit card with a major financial institution with an aggregate credit limit of \$25,000. As at September 30, 2024, the financial institution holds \$25,000 in one Guaranteed Investment Certificate (December 31, 2023 - \$25,000) as collateral on the credit card amount as long as the credit card is active. The restricted cash amount would change if there was any change in the credit limit on the card.

### 5. Accounts Payable and Accrued Liabilities

As at	Se	eptember 30, 2024	Dec	ember 31, 2023
Accounts payable Accrued liabilities	\$	40,877 67,110	\$	497 76,232
	\$	107,987	\$	76,729

The following is an aged analysis of the accounts payable and accrued liabilities:

As at	Se	ptember 30, 2024	Dec	cember 31, 2023
Less than 1 month 1 to 3 months	\$	83,573 15,550	\$	76,232
Greater than 3 months		8,864		- 497
	\$	107,987	\$	76,729

### 6. Deferred gain on acquisition of investments

On July 29, 2022, the Company acquired a portfolio of assets from Cannalncome Fund Corporation ("CiF"). The portfolio consists of public equities, private equities, debt, convertible debt and warrants, having a deemed fair value of \$2,599,356. Olive issued 30,254,247 common shares in consideration for the assets, representing a transaction price of \$0.045 per share based on the market value of Olive shares on the date of the acquisition. Of the difference of \$1,237,915 between fair value at initial recognition and transaction price, \$197,629 was related to the investments with fair value evidenced by a quoted price in an active market or based on a valuation technique that uses only data from observable market inputs and was recognized as a gain on day-one in accordance with IFRS 13 Fair Value Measurement. The remaining \$1,040,286 was recognized as a deferred gain on acquisition of investments. During the year ended December 31, 2022, \$1,156,324 of the deferred gain on acquisition of investments was recognized as a gain in the consolidated statements of loss to the extent that it arises from a change in a factor that market participants would take into account when pricing the assets. During the three and nine months ened September 30, 2024, the deferred gain on acquisition of investments:

Notes to Condensed Interim Consolidated Financial Statements September 30, 2024 (Expressed in Canadian Dollars unless otherwise stated) (Unaudited)

### 6. Deferred gain on acquisition of investments (continued)

	Sep	tember 30, 2024	Dec	December 31, 2023	
Beginning balance	\$	81,591	\$	81,591	
Ending balance	\$	81,591	\$	81,591	

### 7. Share Capital

### a) Authorized share capital

The authorized share capital consists of an unlimited number of common shares without par value.

### b) Common shares issued

	Number of Common Shares	Amount
Balance - December 31, 2022 Common shares issued in settlement of accrued liability (note 5) Share repurchase (i)	<b>110,768,709</b> 1,000,000 -	\$ <b>15,208,812</b> 35,000 (274,605)
Balance - September 30, 2023	111,768,709	\$ 14,969,207

Balance - December 31, 2023	109,174,709	\$ <b>15,172,132</b>
Share repurchase (i)	-	(87,291)
Balance - September 30, 2024	109,174,709	\$ 15,084,841

(i) On December 14, 2022, the Company received approval to undertake, at the Company's discretion, a normal course issuer bid program to purchase up to 10,466,520 of its common shares (the "Bid 2022"). The Bid 2022 commenced on December 16, 2022, and terminated in December, 2023. On January 15, 2024, the Company received approval to undertake a new normal course issued bid program to purchase up to 10,153,620 of its common shares (the "Bid 2024"). The Bid 2024 commenced on January 18, 2024, and and will terminate on January 17, 2025, or on an earlier date in the event that the maximum number of common shares sought in the Bid has been repurchased.

During the three and nine months ended September 30, 2023, the Company repurchased 700,000 and 2,000,000 common shares of the Company for cash consideration of \$20,370 and \$60,530 in accordance with the Bid, respectively.

During the three months ended September 30, 2024, the Company repurchased nil common shares of the Company in accordance with the Bid 2024. During the nine months ended September 30, 2024, the Company repurchased a total 3,030,000 common shares of the Company for cash consideration of \$87,291 in accordance with the Bid 2024. These 3,030,000 common shares are currently held in Treasury pending cancellation.

Notes to Condensed Interim Consolidated Financial Statements September 30, 2024 (Expressed in Canadian Dollars unless otherwise stated) (Unaudited)

### 8. Stock Options

The following table reflects the continuity of stock options for the periods ended September 30, 2024 and 2023:

	Number of Stock Options	Weighted Average Exercise Price
Balance - December 31, 2022 and September 30, 2023	5,150,000	\$ 0.12
Granted	2,500,000	0.05
Balance - December 31, 2023 and September 30, 2024	7,650,000	\$ 0.08

The following table reflects the actual stock options issued and outstanding as of September 30, 2024:

Expiry Date	Exercise Price (\$)	Weighted Average Remaining Contractua Life (years)	Number of I Options Outstanding	Number of Options Vested	Grant Date Fair Value (\$)
April 27, 2025	0.10	0.57	800,000	800,000	65,626
August 9, 2026	0.13	1.86	4,350,000	4,350,000	327,971
November 27, 2028	0.05	4.16	2,500,000	700,000	60,883
	0.08	2.48	7,650,000	5,850,000	454,480

(i) On August 9, 2021, the Company granted a total of 4,350,000 stock options to acquire common shares in the capital of the Company at an exercise price of \$0.125 per share which expire on August 9, 2026. The stock options granted to Officers and Directors vest as follows: 25% vest immediately, 25% on the first anniversary date, 25% on second anniversary date, and 25% on the third anniversary date. The options granted to consultants vest immediately. The fair value of the stock options was estimated to be \$327,971 using Black-Scholes option pricing model on the following assumptions: share price of \$0.10, exercise price of \$0.13, risk free interest rate of 0.88%, an expected yield of 0%, an expected life of 5 years and an expected volatility of 108%. During the three and nine months ended September 30, 2024, stock compensation of \$2,786 and \$15,787, respectively (three and nine months ended September 30, 2023 - \$10,858 and \$43,183, respectively) was recorded in the unaudited condensed interim consolidated statements of income (loss).

(ii) On November 27, 2023, the Company granted a total of 2,500,000 stock options to acquire common shares in the capital of the Company at an exercise price of \$0.05 per share which expire on November 27, 2028. The stock options granted to Officers and Directors vest as follows: 25% vest immediately, 25% on the first anniversary date, 25% on second anniversary date, and 25% on the third anniversary date. The options granted to consultants vest immediately. The fair value of the stock options was estimated to be \$60,883 using Black-Scholes option pricing model on the following assumptions: share price of \$0.03, exercise price of \$0.05, risk free interest rate of 3.76%, an expected yield of 0%, an expected life of 5 years and an expected volatility of 125%. During the three and nine months ended September 30, 2024, stock compensation of \$6,752 and \$20,111, respectively (three and nine months ended September 30, 2023 - \$nil) was recorded in the unaudited condensed interim consolidated statements of income (loss).

Notes to Condensed Interim Consolidated Financial Statements September 30, 2024 (Expressed in Canadian Dollars unless otherwise stated) (Unaudited)

### 9. Basic and Diluted Loss per Share

	Three Months Ended September 30,		Nine Months Ended September 30,		
	2024	2023	2024	2023	
Weighted average number of common shares outstanding - basic and dilutive	109,174,709	111 768 709	109,174,709	111 630 587	

The calculation of basic and diluted income (loss) per share for the three and nine months ended September 30, 2024 was based on the net income and (loss) attributable to common shareholders of \$142,401 and \$(147,715), respectively (three and nine months ended September 30, 2023 – net income of \$17,738 and \$990,108, respectively) and the weighted average number of common shares outstanding of 109,174,709 (three and nine months ended September 30, 2023 – 111,768,709 and 111,630,587, respectively). Diluted income and loss per share for the three and nine months ended September 30, 2024 did not include the effect of 7,650,000 options (three and nine months ended September 30, 2023 – 5,150,000, out-of-the money) as they were either out-of-the-money or anti-dilutive.

### 10. Related Party Balances and Transactions and Major Shareholders

### (a) Related party balances and transactions

Related parties include the Board of Directors, close family members and enterprises that are controlled by these individuals as well as certain persons performing similar functions.

	Three Months Ended September 30,			Nine Mor Septer			
	2024		2023		2024		2023
Marrelli Support Services Inc. ("MSSI") (i) \$	16,176	\$	13,802	\$	52,072	\$	55,124
Marrelli Trust Company Limited (Marrelli Trust") (ii)	2,732		2,107		4,158		3,633
DSA Corporate Services Inc. ("DSA") (iii)	1,560		987		6,797		6,093
Kanaga Capital Corp. ("Kanaga") (iv)	15,000		15,000		45,000		45,000
Celeste Advisors Inc. ("Celeste") (v)	30,000		30,000		90,000		90,000

(i) Fees are related to services of Carmelo Marrelli to act as the Chief Financial Officer ("CFO") of the Company. Carmelo Marrelli is the Managing Director of MSSI. Services were incurred for bookkeeping, accounting and CFO services. As at September 30, 2024, MSSI was owed \$2,403 (December 31, 2023 - \$nil) and this amount was included in accounts payable and accrued liabilities. This amount is unsecured and non-interest bearing.

(ii) The CFO of the Company is a director of Marrelli Trust, corporate trustee, transfer agent and registrar to the Company. Fees are related to shareholder, transfer agent and corporate trustee services provided by Marrelli Trust to the Company. As at September 30, 2024, Marrelli Trust was owed \$2,314 (December 31, 2023 - \$nil). This amount is unsecured and non-interest bearing.

(iii) The CFO of the Company is an officer of DSA. Fees are related to corporate secretarial and filing services provided by DSA. As at September 30, 2024, DSA was owed \$1,220 (December 31, 2023 - \$nil) and this amount was included in accounts payable and accrued liabilities.

(iv) Consulting fees were paid to Kanaga Capital Corp., a Company controlled by Derek Macpherson, the Executive Chairman of the Company. As at September 30, 2024, Kanaga was owed \$nil (December 31, 2023 - \$nil).

(v) Consulting fees were paid to Celeste Advisors Inc., a Company controlled by Samuel Pelaez, the Chief Executive Officer ("CEO"). As at September 30, 2024, Celeste was owed \$nil (December 31, 2023 - \$nil).

Notes to Condensed Interim Consolidated Financial Statements September 30, 2024 (Expressed in Canadian Dollars unless otherwise stated) (Unaudited)

### 10. Related Party Balances and Transactions and Major Shareholders (continued)

### (b) Remuneration of directors and key management

In accordance with IAS 24, key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Company directly or indirectly, including any directors (executive and non-executive) of the Company. Remuneration of directors, the CEO and the CFO of the Company was as follows:

	Three Months Ended September 30,			Nine Months Ende September 30,			
	2024		2023	2024		2023	
Director fees	\$ 11,250	\$	11,250	\$ 33,750	\$	33,750	
Stock-based compensation (Note 8)	9,537		10,858	35,897		43,183	

Please refer to note 10 (a) above for compensation to CEO, CFO and Executive Chairman of the Company.

#### (c) Major shareholders

To the knowledge of the directors and senior officers of the Company, as at September 30, 2024, no person or corporation beneficially owns or exercises control over common shares of the Company carrying more than 10% of the voting rights attached to all common shares of the Company. The holding can change at any time at the discretion of the owners.

None of the Company's major shareholders have different voting rights compared to holders of the Company's common shares.

The Company is not aware of any arrangements the operation of which may at a subsequent date result in a change in control of the Company. To the knowledge of the Company, it is not directly or indirectly owned or controlled by another corporation, by any government or by any natural or legal person severally or jointly.

### 11. Capital Disclosure

The Company considers its capital to consist of share capital, contributed surplus, and deficit. The Company's objectives when managing capital are: (a) to allow the Company to respond to changes in economic and/or marketplace conditions by maintaining the Company's ability to purchase new investments; (b) to give shareholders sustained growth in value by increasing shareholders' equity; while (c) taking a conservative approach towards management of financial risks.

The Company's management reviews its capital structure on an on-going basis and makes adjustments to it in light of changes in economic conditions and the risk characteristics of its underlying investments. The Company's current capital is composed of its shareholders' equity and, to-date, has adjusted or maintained its level of capital by: (a) raising capital through equity financings; and (b) realizing proceeds from the disposition of its investments.

The Company is not subject to any capital requirements imposed by a lending institution or regulatory body, other than Policy 2.5 of the TSX Venture Exchange which requires adequate working capital or financial resources of the greater of (i) \$50,000 and (ii) an amount required in order to maintain operations and cover general and administrative expenses for a period of 6 months. As of September 30, 2024, management believes it is compliant with known requirements. The Company expects that its capital resources will be sufficient to discharge its liabilities as of the current statement of financial position date.

Notes to Condensed Interim Consolidated Financial Statements September 30, 2024 (Expressed in Canadian Dollars unless otherwise stated) (Unaudited)

### 12. Fair Value Measurements

#### Fair value of financial instruments

The Company has determined the carrying values of its financial instruments as follows:

i. The carrying values of cash and cash equivalents, amounts receivable and accounts payable and accrued liabilities approximate their fair values due to the short-term nature of these instruments.

ii. Public investments and non-public investments are carried at amounts in accordance with the Company's accounting policy as set out in Note 2 to the consolidated financial statements for the years ended December 31, 2023 and 2022

There were no transfers to or from level 3 of the fair value hierarchy during the three and nine months ended September 30, 2024.

The following tables illustrate the classification and hierarchy of the Company's financial instruments, measured at fair value in the statements of financial position as at September 30, 2024 and December 31, 2023:

### As at September 30, 2024 - (Investments, at fair value)

	N	oted Prices i Active Markets for ntical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Un	ignificant observable Inputs (Level 3)	Aggregate Fair Value
Publicly traded investments	\$	3,774,018	\$ -	\$	-	\$ 3,774,018
Non-public investments		-	-		1,103,194	1,103,194
Investments in loans and convertible debentures		-	-		1,521,465	1,521,465

#### As at December 31, 2023 - (Investments, at fair value)

		oted Prices i Active Markets for ntical Assets (Level 1)	Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Aggregate Fair Value	
Publicly traded investments	\$	2,884,159	\$ -	\$	-	\$	2,884,159	
Non-public investments		-	-		881,907		881,907	
Investments in loans and convertible debentures		-	-		1,527,573		1,527,573	

Notes to Condensed Interim Consolidated Financial Statements September 30, 2024 (Expressed in Canadian Dollars unless otherwise stated) (Unaudited)

### 12. Fair Value Measurements (Continued)

#### Level 3 hierarchy:

The following table presents the changes in fair value measurements of financial instruments classified as Level 3. These financial instruments are measured at fair value utilizing non-observable market inputs. The net change in unrealized gains is recognized in the statements of loss.

#### Non-public investments:

Investment at fair value	ba	Opening Ilance at anuary 1	F	urchase		Net gain (loss)	t	Fransfer o public vestment	in	terest come shares		Ending alance	
September 30, 2024 December 31, 2023	\$ \$	881,907 632,867	\$ \$	100,100 647,692	\$ \$	112,400 (398,652)	\$ \$	(51,000) -	\$ \$	59,787 -	• •	103,194 881,907	

### Investments in loans and convertible debentures:

Investment at fair value	Opening balance at January 1 Purchases	Conversion of convertible Realized debentures gain	Interest income	Unrealized Ending loss balance
September 30, 2024 December 31, 2023	\$ 1,527,573 \$ - \$ 1,489,789 \$ 935,78 <sup>2</sup>	\$-\$- \$(1,258,923) \$ 362,126	, ,	

Within Level 3, the Company includes non-public company investments and investments in convertible debentures. The key assumptions used in the valuation of these instruments include (but are not limited to) the value at which a recent financing was done by the investee, company-specific information, trends in general market conditions, the marketability of the shares and subsequent transactions.

The following table presents the fair value, categorized by key valuation techniques and the unobservable inputs used within Level 3 as at:

#### September 30, 2024

Investment name	Valuation technique	Fair value	Unobservable inputs
Non-public investments Investment in loans and	Recent financing approach	\$ 1,103,194	Transaction price
	Recent financing approach	1,521,465	Transaction price

Notes to Condensed Interim Consolidated Financial Statements September 30, 2024 (Expressed in Canadian Dollars unless otherwise stated) (Unaudited)

### 12. Fair Value Measurements (Continued)

Level 3 hierarchy (continued):

December 31, 2023

Investment name	Valuation technique	Fair value	Unobservable inputs
Non-public equities and warrants	Recent financing approach	\$ 881.907	Transaction price
Investment in loans an	<b>a</b> 11	÷	·····
debentures	Recent financing approach	1,527,573	Transaction price

As the valuation of investments for which market quotations are not readily available and are inherently uncertain, the values may fluctuate materially within short periods of time and are based on estimates, and determinations of fair value may differ materially from values that would have resulted if a ready market existed for the investments.

For those investments valued based on a transaction price, management has determined that there are no reasonably possible alternative assumptions that would change the fair value significantly as at September 30, 2024. A 10% decrease (increase) on the fair value of these investments will result in a corresponding decrease (increase) of approximately \$262,000 in the total fair value of the investments. The Company has applied a marketability discount of 0% to its non-public investments valued based on recent financing. Had the Company applied a marketability discount of 5% it would have resulted in a corresponding decrease of approximately \$131,000 in the total fair value of the investments. While this illustrates the overall effect of changing the values of the unobservable inputs by a set percentage, the significance of the impact and the range of reasonably possible alternative assumptions may differ significantly between investments, given their different terms and circumstances.

The sensitivity analysis is intended to reflect the uncertainty inherent in the valuation of these investments under current market conditions, and its results cannot be extrapolated due to non-linear effects that changes in valuation assumptions may have on the fair value of these investments. Furthermore, the analysis does not indicate a probability of such changes occurring and it does not necessarily represent the Company's view of expected future changes in the fair value of these investments. Any management actions that may be taken to mitigate the inherent risks are not reflected in this analysis.

### 13. Commitments and contingencies

From time to time, the Company may be named as a party to claims or involved in proceedings, including legal, regulatory and tax related, in the ordinary course of its business. While the outcome of these matters may not be estimable at period end, the Company makes provisions, where possible, for the estimated outcome of such claims or proceedings. Should a loss result from the resolution of any claims or proceedings that differs from these estimates, the difference will be accounted for as a charge to net income (loss) in that period. As at September 30, 2024, the Company does not have any outstanding claims against it.